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Inherited deficiency in themitochondrial protein frataxin (FXN) causes the rare disease Friedreich’s ataxia (FA),
forwhich there isnosuccessful treatment.We identifieda redoxdeficiency inFAcells andused this tomodel the
disease.Wescreeneda 1600-compound library to identify existingdrugs,which could beof therapeutic benefit.
We identifiedthe topicalanestheticdyclonineasprotective.Dyclonine increasedFXNtranscriptandFXNprotein
dose-dependently in FA cells and brains of animal models. Dyclonine also rescued FXN-dependent enzyme
deficiencies in the iron–sulfur enzymes, aconitase and succinate dehydrogenase. Dyclonine induces the Nrf2
[nuclear factor (erythroid-derived 2)-like 2] transcription factor, which we show binds an upstream response
element in the FXN locus. Additionally, dyclonine also inhibited the activity of histone methyltransferase G9a,
known to methylate histone H3K9 to silence FA chromatin. Chronic dosing in a FA mouse model prevented a
performance decline in balance beam studies. A human clinical proof-of-concept study was completed in
eight FA patients dosed twice daily using a 1% dyclonine rinse for 1 week. Six of the eight patients showed an
increase in buccal cell FXN levels, and fold induction was significantly correlated with disease severity.
Dyclonine represents a novel therapeutic strategy that can potentially be repurposed for the treatment of FA.
INTRODUCTION
Friedreich’s ataxia (FA) is a severe neurodegenerative disease
that is the most common autosomal recessive inherited move-
ment disorder (1). There is no cure or effective treatment for
FA. The disease causes degeneration and demyelination in
dorsal root ganglion (DRG) neurons and spinocerebellar tracts,
resulting in movement and speech disorders (2,3). Symptoms
begin between the ages of 5–15 years, and patients are often
wheelchair bound within 10–15 years of diagnosis. Early
death is common and usually occurs from cardiac complications
(4). FA is caused by a decrease in the mitochondrial protein fra-
taxin (FXN gene), which has been shown to have roles in iron–
sulfur cluster synthesis, iron transfer and antioxidant defense
(1,5–8). The decrease in FXN stems from an accumulation of
GAA triplet repeats in the first intron of the gene through inher-
itance (9–11). Here, we report on screening and identification
of a potential therapeutic for FA. We previously identified anti-
oxidant defects in DRG cells of an FA mouse model (12). Using
this to develop a specific hypothesis for disease pathogenesis, we
designed a cellular disease model for FA in order to identify
a potential treatment. The cell model identified dyclonine, and
we have shown that it induces FXN in cells, animal models
and FA patients through a novel mechanism. Dyclonine is
an oral anesthetic used to provide topical anesthesia to mucous
membranes through sodium channel inhibition (13). It is the
active ingredient in Sucrets, an over-the-counter throat
lozenge, and has been in use for over 50 years (14). Additionally,
dyclonine is used during dental examinations and procedures to
numb mucous membranes of the mouth (15).
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Figure 1. High-throughput screening reveals that dyclonine protects FA patient fibroblasts from diamide stress. (A) Effect of antioxidant inhibitors on 50B11 cell
viability with FXN knockdown. Eleven inhibitors of thiol-related antioxidants were tested in an siRNA-mediated, FXN-deficient 50B11 DRG cell line [10 mM anti-
mycin A, 1 mM auranofin, 100 mM BSO, 100 mM carmustine, 10 mM diamide, 0.1% diethyl maleate (DEM), 0.1% ethanol, 0.03% H2O2, 1 mM L-glutathione
(L-GSH), 0.1% phenethyl isothiocyanate (PEITC), 100 mM dichloronitrobenzene (DCNB) and 1 mMN-methyl protoporphyrin (NMP)]. Cell viability was measured
with Calcein-AM after 24 h and normalized to untreated control (n ¼ 3). Increased sensitivity to cell death was induced by inhibitors of thiol-related antioxidants
diamide and auranofin in FXN knockdown cells compared with AllStars non-targeting siRNA negative control. (B) FXN-dependent sensitivity to diamide is dose-
dependent in 50B11 cells. Cell viability was measured with Calcein-AM after 24 h of treatment with 3–300 mM diamide and normalized to untreated control (n ¼ 3).
(C) Friedreich’s patient cells are sensitive to diamide. To confirm these effects in patient cells with low FXN, we tested 100 mM diamide in fibroblasts and
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RESULTS
FXN-deficient cells are sensitive to the thioredoxin-oxidant
diamide
There is ample support for dysregulated antioxidant defenses in
FA (12,16–18). We screened that12 inhibitors of thiol antioxi-
dants were screened in FXN-deficient DRG neural cells, chosen
since the DRGs are the primary site of disease pathogenesis
(Fig. 1A and B) .Measuring viable cells with Calcein-AM stain-
ing, the thioredoxin-oxidant diamide produced the greatest sen-
sitivity (19). To confirm this phenotype in patient cells, we found
that FXN-deficient FA fibroblasts and lymphoblasts were also
clearly more sensitive to diamide treatment than healthy controls
(Fig. 1C). Diamide is a specific thiol oxidant that causes oxida-
tive damage and results in cell death (20,21). In the FA patient
fibroblasts, a robust high-throughput screening assay based on
diamide sensitivity was developed, with an average Z′-score of
0.7. We then screened a 1600-compound library of drugs that
have been approved for use in human trials, and identified pro-
tective drugs (Fig. 1D). After the initial screen, multiple rounds
of hit confirmation, and then concentration response curves, 33
drugs were found that reproducibly protected the patient cells
from the thiol stress induced by diamide (Supplementary Mater-
ial, Table S1). Of the drugs found to protect FA fibroblasts from
diamide-induced oxidative stress, dyclonine was one of the most
potent (Fig. 1E).
Dyclonine induces FXN in patient cells and in animal model
tissues
Multiple mechanisms of action of protection from diamide were
possible. One is reactivation of FXN expression, since its defici-
ency mediated the sensitivity to diamide. Thus, all 33 confirmed
that screening hits including dyclonine were tested for their
ability to induce FXN protein levels in the absence of diamide
(Supplementary Material, Table S1). Of the compounds found
to increase FXN in FA patient cells, we eliminated some because
of safety concerns (i.e. cotinine and nifursol), and others because
of their primary use is in veterinary medicine (i.e. oxfendazole)
(22–24). We chose to follow-up with dyclonine because of its
potency of diamide protection, reproducibility of FXN induction
and safe use in humans for decades. FA patient lymphoblasts
treated with dyclonine show clear induction of FXN protein
after 48 h of dyclonine exposure (Fig. 2A). Additionally, FXN
mRNA transcript measured by RT-PCR is also dose-dependently
increased after 24 h drug treatment in FA lymphoblasts (Fig. 2B).
We observed induction of FXN in multiple animal models after
intraperitoneal or oral dosing. FA-YG8 [hFXN+/2 with FXN
(GAA)190 expansion; mFxn
2/2] transgenic mice (8) dosed for
1 week once daily with dyclonine i.p. or p.o. showed a clear
induction of FXN protein in cerebellar lysate (Fig. 2C).
In addition, to explore the effects of dyclonine in an additional
model with chronic dosing, we treated FA-PandKIKO mice
[mFxn+/2 with FXN (GAA)230 expansion; mFxn
2/2] with
25 mg/kg dyclonine for 4 weeks p.o. This higher dose was
chosen in an attempt to ascertain the maximum induction of
FXN within the limits of dyclonine solubility. Thus, showing
dyclonine can reverse the in vivo FXN protein defect in an add-
itional FA model at a higher dose and chronic duration (Fig. 2D).
These chronic studies resulted in no observable changes in sed-
ation, feeding behavior or gross pathology. We observed these
effects on FXN in multiple additional tissues, including heart
and liver (Supplementary Material, Fig. S1).
Dyclonine activates the Nrf2 pathway
Of the 33 drugs that protected FA patient cells from diamide
stress, some drugs were reported antioxidant response element
(ARE)/nuclear factor (erythroid-derived 2)-like 2 (Nrf2) indu-
cers in literature such as ebselen (25). Nrf2 is a transcription
factor that responds to oxidative and thiol stress by binding
AREs and driving the expression of multiple antioxidant and
anti-inflammatory target genes including heme oxygenase 1
(HMOX1), NAD(P)H dehydrogenase (quinone) (NQO1) and
glutathione peroxidase (GPX4) (26,27). We explored the activity
of all 33 drugs as ARE/Nrf2 inducers for their ability to stimulate
ARE-luciferase reporter system activity (Supplementary Mater-
ial, Table S1), including dyclonine which dose-dependently
drove induction of ARE-luciferase (Fig. 3A). Remarkably, mul-
tiple drugs that increased ARE-luciferase expression were also
found to be FXN inducers (Supplementary Material, Table S1).
In addition, after oral dyclonine dosing in the FA-YG8 mouse
model of FA drives a dose-dependent increase in known Nrf2-
target proteins in cerebellar lysate including heme oxygenase
(HO1), NQO1 and GPX4 (Fig. 3B). Thus, dyclonine is an activa-
tor of the ARE/Nrf2 pathway.
Evolutionarily conserved Nrf2-binding sites (AREs) exist in
the FXN gene and are functional Nrf2-binding sites
We studied the mechanism of induction of FXN by dyclonine
with regard to Nrf2. If dyclonine induces FXN through the
Nrf2 pathway, then there should be active Nrf2-binding sites,
i.e. AREs (28) within the FXN locus that are triggered by dyclo-
nine exposure. Seven potential ARE sites were found between
20 kb upstream and 5 kb downstream of the FXN locus
lymphoblasts and found that patient cells were more sensitive to diamide compared with healthy control cells. (D) Results of high-throughput screen for drugs that
protect from diamide toxicity. Significance is shown comparing healthy volunteer and FA patient lines grouped together. This cell-based assay in FA patient fibroblast
cell line 1134 was furtheroptimized for high-throughput screening in 96-well plates,with a meanZ′-value of 0.75 (n ¼ 25).This platformwas used to screena libraryof
1600 drugs that have been approved for clinical use. FA fibroblasts were pretreated with 10 mM test compound, DMSO (negative control) or 300 mM dithiothreitol
(DTT) (positive control) for 24 h and followed by 100 mM diamide for 24 h. Cell viability was measured with Calcein-AM. Screening data (diamide + all drugs) are
the mean of two replicates and presented as fold above DMSO + diamide control. Arrow indicates dyclonine response. Mean + SD for the 1600 drugs was 1+0.3;
mean + SEM was 1+0.01. Compounds that rescued from diamide toxicity greater than mean + 2× SD advanced to secondary screening, which included replication
of protective effect in a concentration-dependent manner, 0.01–10 mM. (E) An example of dose-dependent protection by dyclonine. Dyclonine was added to FA
fibroblast line 1134 for 24 h before 100 mM diamide treatment, and Calcein-AM viability is shown as fold above DMSO + diamide control. Intrinsic effect:
2.1+0.49-fold above DMSO + diamide control; EC50: 0.36+0.25 mM (n ¼ 3). (F) Chemical structure of dyclonine. The plotted data in A, B, C and E display
mean responses and error bars represent SD (n ¼ 3–4). ∗P , 0.05, ∗ ∗P , 0.001 relative to control, t-test.
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Figure2.Dyclonine induces FXN in cultured FA patient cells and FA mouse model cerebellum in vivo. (A) Dyclonine increases FXN protein expression in FA patient
lymphoblast cell lines. To test if the mechanism of protection from diamide toxicity for dyclonine was through an increase in FXN protein levels, FA lymphoblasts
were treated with 0.3–10 mM dyclonine or vehicle control (0.1% DMSO). Total protein was collected after 48 h, and lysates were probed by western blot analysis for
FXN expression and normalized tob-actin. The plotted data represent the mean fold change in FXN protein in drug-treated cells, normalized to vehicle control. Error
bars represent SEM. ∗∗P , 0.01, t-test (n ¼ 2–15). A representative blot is shown for FA patient lymphoblast line 15850 treated with 10 mM dyclonine for 48 h. (B)
Dyclonine increases FXN transcript levels in FA patient lymphoblasts. FA lymphoblast cell line 14518 was treated with 3–30 mM dyclonine or vehicle control (0.1%
DMSO). RNA was analyzed after 24 h by RT-PCR with expression with primers for FXN normalized to b-actin. The plotted data represent the mean fold change in
FXN transcript in drug-treated cells normalized to vehicle control. Error bars represent SEM. ∗P , 0.05, ∗∗P , 0.01, (n ¼ 4), t-test. (C) Dyclonine increases FXN
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(Table 1). The top three potential ARE sites had excellent ARE
scores of 12.9, 12.5 and 8.0, and were found 4.9, 5.6 and 16.7 kb,
respectively, upstream of the transcription start site for FXN
(Supplementary Material, Fig. S2).
All potential ARE sites were compared among the FXN loci of
the great apes aligned with Clustal W (Homo sapiens, Pan troglo-
dytes, Gorilla and Pongo abeli) in the 10 kb region upstream of
the FXN gene (29). The top three canonical ARE sites were per-
fectly conserved at all 21 bp among all four species. Chromatin
Immunoprecipitation (ChIP) experiments were carried out in
drug-treated FA patient lymphoblasts, using an antibody to
pull down Nrf2 and PCR using primers to the potential ARE
sites in FXN or control Nrf2-target genes. These demonstrate
that dyclonine enriches binding of Nrf2 to the ARE site in
HO1 and the FXN gene 16 722 bp upstream of the start site
(Fig. 3C). Thus, there are active ARE sites in the FXN gene.
Epigenetic effects of dyclonine on the FXN locus
In FA, inheritance of larger GAA expansions causes increased
epigenetic silencing, decreased FXN expression, and increased
disease severity (6,30). The mechanism of dyclonine-induced
FXN re-expression was investigated in patient lymphoblast
cells bearing differential GAA repeats (Fig. 4A). The ability of
dyclonine to induce FXN expression is directly correlated with
dose and repeat length, in that larger, expanded, more silenced
FXN loci were more ‘reactivatable’ by dyclonine.
Thus, as a result of Nrf2 activation or as a cause of it, dyclonine
has an ‘unsilencing’ epigenetic activity. Dyclonine has been
reported to have inhibitory activity on histone lysine methyl-
transferase G9a, which is known to methylate Histone H3K9
(PubChem, assay ID 504332). Inhibitory methylation of histone
H3K9 is a known epigenetic mark at the FXN locus (31–34). We
found that dyclonine inhibited histone methyltransferase G9 in
lymphoblast nuclear extracts (Fig. 4B). Recently, sulfora-
phane’s activation of Nrf2 has been demonstrated to occur
through an epigenetic unsilencing of the Nrf2 locus itself
(35,36). Thus, either dyclonine  G9A  FXN and Nrf2, or
dyclonine  Nrf2  FXN, are possible.
Dyclonine inhibits sodium channels, but does not produce
systemic anesthesia
The mechanism of dyclonine’s well-known anesthetic actions
is through inhibition of sodium channels (37), though the con-
centrations were not readily available in literature. We tested
the inhibitory effect of dyclonine using patch-clamp electro-
physiology on sodium channel NaV1.2 currents, because of its
presence on neurons and potential for sedative effects (38,39).
As expected, we found that dyclonine clearly inhibited the
sodium channel current in N1E–115 neuroblastoma cells. (Sup-
plementary Material, Fig. S3). Since dyclonine is used primarily
as a topical anesthetic (13), we tested whether dyclonine induced
systemic anesthesia when dosed systemically at doses relevant
for FXN induction. We measured hot plate response times in
mice dosed with 3 mg/kg dyclonine i.p., and observed no
delay in hot plate response over 1.5 h (Supplementary Material,
Fig. S4), meaning dyclonine does not produce systemic anesthe-
sia at these doses.
Rescue of biochemical and behavioral end points of FXN
deficiency by dyclonine
FXN plays a functional role in iron–sulfur cluster biogenesis
(40,41), and FXN knockdown of patient cells causes defects in
the activity of the iron–sulfur cluster-containing enzymes, aco-
nitase and succinate dehydrogenase (42,43). We observed in-
duction of aconitase activity in patient lymphoblast extracts
after dyclonine treatment for 24 h in three FA patient lympho-
blast lines (Fig. 5A). Also, dyclonine treatment for 1 week
increased FA-YG8 mouse cerebellar aconitase activity (Fig. 5B).
In addition to aconitase, succinate dehydrogenase activity was
measured in mouse liver and daily oral dyclonine treatment for
4 weeks reversed the succinate dehydrogenase defect in mouse
liver lysate (Fig. 5C). Additionally, our behavioral analysis of
FA-PandKIKO mice demonstrates that 16 mm level beam cross-
ing time is the most reproducible measure in these FXN-deficient
mice. After 4 weeks of oral dosing with 25 mg/kg dyclonine,
vehicle-dosed FA mouse balance beam time worsened by
on average 8 s, whereas dyclonine-dosed animals not only did
not worsen, but improved their times across (Fig. 5D and Sup-
plementary Material, Fig. S6). Additionally, analysis of video
recordings of mouse beam performance revealed improvement
inerrors (footslips)after treatmentwithdyclonine (Supplementary
Material, Fig. S6). There were no significant changes in body
weight or feeding behaviors (Supplementary Material, Table S2)
Oral dosing with dyclonine rinse solution in humans induces
FXN in buccal cells
Since dyclonine is FDA-approved as an oral rinse, and FXN
expression can be investigated non-invasively in oral mucosa
cells after collection by cheek swab (44,45). Thus, an
investigator-initiated clinical study was carried out to investi-
gate the effect of dyclonine on cells in FA patients. Patients
came in for initial pre-dosing swab to establish baseline and to
protein concentration in FA-YG8 mouse cerebellum. To determine the ability of dyclonine to reverse the in vivo FXN protein defect, FA-YG8 transgenic mice
[hFXN+/2 with FXN (GAA)190 expansion; mFxn
2/2] were treated with 1–10 mg/kg dyclonine for 1 week i.p. or p.o. Cerebellar lysates were probed by western
blot analysis for FXN expression and normalized to b-actin. The plotted data represent the mean fold change in FXN protein in drug-treated mice normalized to
vehicle control. Error bars represent SEM. ∗P , 0.05, ∗∗P, 0.01, t-test (n ¼ 3–10 and 11–12 months of age). A representative blot is shown for cerebellum
from FA-YG8 mice treated with 10 mg/kg dyclonine for 1 week. FA-YG8 [hFXN+/+ with FXN (GAA)190 expansion; mFxn
2/2] mice with two copies of transgene
used as a control. (D) Dyclonine increases FXN protein levels in FA-PandKIKO mouse cerebellum. To determine the ability of dyclonine to reverse the in vivo FXN
protein defect in an additional FA model at a higher dose and duration, FA-PandKIKO mice [mFxn+/2 with FXN (GAA)230 expansion; mFxn
2/2] were treated with
25 mg/kg dyclonine for 1 or 4 weeks p.o. Cerebellar lysates were probed by western blot analysis for FXN expression and normalized to b-actin. The plotted data
represent the mean fold change in FXN protein in drug-treated mice normalized to vehicle control. Error bars represent SEM. ∗∗P , 0.01, t-test. (n ¼ 3–17 and
8–10 months of age). A representative blot is shown for cerebellum from FA-YG8 mice treated with 25 mg/kg dyclonine for 1 week. Wild-type C57BL/6 mice
used as a control.
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Figure 3.Dyclonine drives an induction of Nrf2 through the AREs in FXN gene. (A) Dyclonine increases the expression of ARE-luciferase reporter gene. To explore
the mechanism of FXN induction by dyclonine, effects on the nrf2-target ARE were evaluated in a reporter HeLa cell line transduced with ARE-luciferase. Cells were
treated with 1.25–10 mM dyclonine or vehicle control (0.1% DMSO). After 24 h, cells were lysed and luciferase activity was measured on a plate reader. The plotted
data represent the mean fold change in luminescence in drug-treated cells normalized to vehicle control. (+) control ¼ 5 mM sulforaphane. Error bars represent SEM.
∗∗P , 0.01, t-test (n ¼ 3). (B) Dyclonine increases nrf2-target protein expression in the FA mouse cerebellum. FA-YG8 transgenic mice [hFXN+/2 with FXN
(GAA)190 expansion; mFxn
2/2] were treated with 1–10 mg/kg dyclonine for 1 week p.o. Cerebellar lysates were probed by western blot analysis for nrf2-target
proteins HO1, NQO1, and GPX4 expression and normalized tob-actin. The plotted data represent the mean fold change in FXN protein in drug-treated mice normal-
ized to vehiclecontrol. Error bars represent SEM. ∗P , 0.05, ∗∗P , 0.01, t-test. (n ¼ 3). A representative blot is shown for cerebellumfrom FA-YG8mice treated with
10 mg/kg dyclonine for 1 week. (C) Dyclonine induces nrf2 binding to ARE sites in Fxn and Hmox1. Multiple ARE sites were found upstream of FXN gene (Sup-
plementary Material, Fig. S2). The top two candidates 5597 and 16722 bp upstream were selected from position weight. ChIP assays were performed to determine the
binding of Nrf2 to these sites and the promoter ofHmox1 as a positive control. FA lymphoblasts (GM14518, GM15850 and GM16220) were treated with vehicle (0.1%
DMSO), 5 mM dyclonine or 5 mM of the nrf2-inducer dimethyl-fumarate for 24 h. Chromatin was immunoprecipitated with anti-nrf2 antibody or anti-IgG negative
control and by PCR for target loci. The plotted data represent the mean fold enrichment of PCR product with Nrf2 pulldown compared with IgG control. This
shows increased amplification of regions of DNA for both the ARE sites, 16 722 bp upstream of fxn and Hmox1 after dyclonine treatment. Error bars represent
SEM. ∗P , 0.05, ∗∗P , 0.01, t-test (n ¼ 5 individual pulldowns per condition, n ¼ 3 per experiments).
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receive dyclonine. Patients or caregivers dosed with dyclonine by
an oral rinse for 6–7 days twice daily, and then came in for a final
cheek swabbing for buccal cells. These blinded samples were
then sent for analysis. FXN protein was analyzed by the clinically
validated dipstick immunoassay (44,45). We modified these
methods by further by normalizing FXN to mitochondrial cyto-
chrome oxidase expression, i.e. FXN/Complex IV (CIV). Four
repeats of the dipstick immunoassay were performed per patient
sample. Of the 8 patients who received dyclonine, six experienced
FXN increase (ranging from 60 to 480% induction), and two
experienced no induction (Table 2). Interestingly, patients with
greater neurological impairment as measured by the Friedreich’s
ataxia rating scale (FARS) (46,47), experienced greater FXN
induction (Fig. 6A). Other correlations that were also significant
included the Functional Disability Score (FDS) and Z2 ataxia
functional composite score (Fig. 6B and C) (48). While the correl-
ation of FXN response with GAA repeat length was not significant
(Supplementary Material, Fig. 6D), this trend could underlay the
differential response seen in Figure 4A.
DISCUSSION
FA is caused by inheritance of (GAA)n expansions in intron 1 of
the nuclear FXN gene that decreases its expression to about 20%
of normal. All consequences of Friedreich’s are thought to result
from this epigenetic silencing of FXN (5,6,11,49). There is cur-
rently no approved or effective therapy for this ultimately lethal
disease that currently affects approximately 6000 in the USA and
20 000 in Europe (1). We identified a biochemical deficiency in
Friedreich’s patient cells to design and perform a drug screen,
and have identified a potential treatment for the disease that
rescues FXN deficiency as well as downstream consequences
in cells, animal models and in FA patients.
Our previous microarray of Friedreich’s mouse model DRGs
indicated defects in thioredoxin reductase, thiol-antioxidant
transcripts and a deficiency in Nrf2 activity in FXN knockdown
cells (12). Also, a deficiency in Nrf2 activation was noted in Frie-
dreich’s fibroblasts (18). Taken together, these data suggested
that FXN deficiency may cause deficiency in Nrf2 activation
or the related mitochondrial thioredoxin reductase pathway
(50), which leads to decreased mitochondrial antioxidant protec-
tion, increased reactive oxygen species, inflammation and neu-
rodegeneration (51).
Given the data on thiol antioxidant deficiency in mouse DRG
(12), and previous data on antioxidant deficiency in FA fibroblasts
(12,16,17), we tested poisons of thiol antioxidants in a FXN-
deficient DRG cell line (Fig. 1A). In these cells, diamide and
auranofin were more toxic to FXN knockdown cells compared
with controls, whereas hydrogen peroxide (H2O2) and buthionine
sulfoxamine (BSO) displayed little to no difference. This was
interesting because diamide oxidizes thioredoxin (52), and aura-
nofin is an inhibitor of thioredoxin reductase (53). These data
support the idea that, in the contextof thedorsal rootganglia, thior-
edoxin reductase is an important antioxidant system. Others have
shown that, in neural mitochondria, thioredoxin reductase is the
dominant antioxidant system (54,55). We examined FA patient
cells and also observed increased cell death after diamide treat-
ment which was reversed by the reductant dithiothreitol (DTT),
confirming a thiol-oxidant mechanism (Fig. 1C).
To expedite the search for clinical candidates, we took a repur-
posing approach and examined a collection of 1600 drugs with
mostly known pharmacokinetic and safety profiles. Our initial
screen identified 100 protective hits in a range of drug classes,
of which 33 were found to be reproducibly dose-dependent,
for a hit rate of 2.5% (Supplementary Material, Table S1).
One of the strongest hit in terms of efficacy and potency at pro-
tecting from diamide stress was dyclonine, the active agent in
Sucrets. Dyclonine was initially characterized as an anti-
epileptic (56), but through its sodium channel inhibitory
properties it has been used for anesthesia since 1955 (13). Dyclo-
nine’s protective effect could potentially be due to multiple
mechanisms, including increased mitochondrial biogenesis,
Fe/S cluster biogenesis, iron binding or others. Since all FA con-
sequences are the result of deficient FXN expression, we
explored whether dyclonine was able to induce FXN in FA
patient cells and the animal model (Fig. 2). We discovered an in-
duction of FXN protein, and this was supported further with
dose-dependent increases in FXN mRNA by RT-PCR. This
has implications for therapy, since dyclonine rescues the
protein deficiency that causes the disease in FA lymphoblasts
and fibroblasts. In animal models of FA, we observed a clear
2-fold induction in FXN protein in two mouse models, in mul-
tiple tissues including cerebellum, liver and heart (Fig. 2C and
D, and Supplementary Material, Fig. S1), two of which (cerebel-
lum and heart) are major sites of disease pathogenesis. Our
animal studies included intraperitoneal and oral dosing, with
Table 1. ARE sites in human FXN gene
Position Position relative
to FXN
Direction DNA strand Sequence PWM score Evolutionarily
conserved (95% CI)
71633757 216 722 Antisense Non-template ACCATGTGACAATGCCCACTT 7.80 Yes
71634506 215 973 Sense Template CCTGGGTGACAGAGCAAGACT 12.30 No
71636687 213 792 Antisense Non-template AGGAACTGACTCCGCACAAGA 10.30 No
71639782 210 697 Antisense Non-template AGTAGATGACCCAGCTGATAG 8.90 No
71643186 27293 Sense Template ACAGTGTGACTATGCTCGACT 10.20 No
71644882 25597 Antisense Non-template GACTCATGACTCAGCCAGTCC 12.50 Yes
71645605 24874 Antisense Template GACCGGTGACTTTGCAAGTTA 12.90 Yes
71651446 967 Antisense Template AACCTTTGACTGGGCTGGAAA 4.20 No
71654599 4120 Sense Template GGGATGTGACGGGGCTGCGTC 1.20 No
FXN gene starts at 71650479 and ends at 71715094(64 615 bp). GAA-repeat insertion is 1731 bp downstream of FXN exon-1 start site. Position weight matrix (PWM)
score from Wang et al. (28). Searched for the regular expression of ARE consensus sequence: TGAC[ACTG]{3}GC from 20 kb upstream to 5 kb downstream of FXN.
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drug exposures from 4 days to 4 weeks. In all, we have done 12
independent in vivo studies with dyclonine with between 3 and 6
mice per group, and each study supported an induction in FXN by
dyclonine. Since FA patients are asymptomatic when their FXN
levels are 40–50% of normal levels, an induction of 2-fold
should boost patient FXN levels into this range, and alleviate
consequences of FXN deficiency (57).
Early on in our development efforts, we noted that a few of the
drugs we found to protect from diamide were also Nrf2 inducers
in literature. Nrf2 translocates to the nucleus in response to oxi-
dative stress (and especially thiol stress) and binds to AREs in
target genes (27). Dyclonine had never been described to
induce Nrf2, and we demonstrated a dose-dependent stimula-
tion, and that multiple Nrf2-target proteins are elevated after
treatment with dyclonine in both FA patient cells and animal
model tissues (Fig. 3B). To investigate if the induction of FXN
was Nrf2-mediated, we used bioinformatics to identify ARE
sequences in the FXN locus, finding three ARE sites upstream
of the transcription start site of FXN that are completely con-
served across ape evolution (Table 1 and Supplementary Mater-
ial, Fig. S2). The functionality of ARE sites was verified by ChIP
and pull down with an Nrf2 antibody (Fig. 3C). Thus the induc-
tion of FXN is likely the result of recruitment of Nrf2 to adjacent
ARE sites. Data also suggest that other Nrf2 inducers will reacti-
vate FXN expression.
We observe that dyclonine has a differential effect on FXN
re-expression from alleles of different expansion length. Specif-
ically, longer GAA alleles, which experience greater epigene-
tic silencing, are more ‘reactivatable’ by dyclonine in cells
(Fig. 4A), and this is consistent with what is observed in patients
(Fig. 6C). There is precedent for Nrf2 activation having epigen-
etic effects on genes (35,58–60). There is also recent precedent
that the classical Nrf2-inducer sulforaphane may be working
through epigenetic unsilencing of the Nrf2 locus (35,36). Dyclo-
nine has been reported to have inhibitory activity on histone
lysine methyltransferase G9a, which is known to methylate
histone H3K9 (PubChem, assay ID 504332). Inhibitory methy-
lation of histone H3K9 is a known epigenetic mark at the FXN
locus (31–34). And we observed experimentally that dyclonine
inhibited histone methyltransferase G9 in lymphoblast nuclear
extracts (Fig. 4B). These data support either of two mechanisms,
i.e. that dyclonine induces Nrf2, and Nrf2 through its epigenetic
unsilencing effects reactivates FXN; or that dyclonine sup-
presses histone methyltransferase G9, which in turn reactivates
both the FXN locus and the Nrf2 locus.
Since dyclonine is an anesthetic whose pain ameliorating
effects are mediated through sodium channel inhibition, there
could be concern of the sedative potential of inhibiting neuronal
NaV1.2 sodium channels (61). Additionally, sodium channel
blockers are used to treat cardiac arrhythmias and alteration of
heart rate would be a concern prior to treatment FA patients
with systemic dyclonine. Since there were no data in the litera-
ture about the specific concentrations at which this occurred,
we examined inhibition of NaV1.2 currents using patch-clamp
electrophysiology. As expected, there was clear dose-dependent
inhibition with an IC50 of 6 mM. This IC50 is 30-fold higher
than our EC50 for protection from diamide in FA fibroblasts,
and we observe FXN induction in FA lymphoblasts with 1 mM
dyclonine. Additionally, after 4 weeks of chronic daily dosing
in mice, no sedation or adverse phenotype was observed.
To verify that there was no systemic peripheral anesthesia
from ingestion of a topical anesthetic at the doses that induce
FXN reactivation, we measured hot plate response and found
no delay. Finally, we tested 20 sodium channel inhibitors or
anesthetics including lidocaine, bupivicaine and propofol and
none were significantly active in the diamide protection assay.
Taken together, this reduces the concern that the protective
Figure 4. Dyclonine exerts epigenetic effects. (A) Dyclonine induction of FXN
transcript levels in healthy and FA patient lymphoblast cells with varying
GAA-repeat length. Healthy and FA patient lymphoblasts (GM16216,
GM16197 and GM14518) were treated with 30 mM dyclonine or vehicle
control (0.1% DMSO). RNA was analyzed after 24 h by RT-PCRwith expression
with primers for FXN normalized to b-actin. GAA, number of GAA repeats on
FXN allele with less insertions. The plotted data represent the mean fold
change in FXN transcript in drug-treated cells normalized to vehicle control for
that cell line. Error bars represent SEM. ∗P , 0.05, ∗∗P , 0.01, t-test (n ¼ 4).
The induction of Fxn mRNA increases with GAA repeat length. (B) Dyclonine
inhibits histone methyltransferase activity. Histone methyltransferase G9a
(G9aHMTase) activity, which specifically methylates histone H3K9, was mea-
sured in nuclear extracts of healthy lymphoblast cells treated with drug for
60 min. Negative controls are 0.1% DMSO vehicle-treated cells; positive
controls are cells treated with G9aHMTase-specific inhibitor 1 mM Bix01294.
The plotted data represent the mean absorbance at 450 nm which reflects
G9aHMTase activity. Error bars represent SEM. ∗P , 0.05, ∗∗P, 0.01, t-test.
(n ¼ 4).
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actions of dyclonine are mediated through sodium channel
blockade, since the doses required for FXN activation are
lower than those for sodium channel engagement.
The most well-defined downstream function for mammalian
FXN is in iron–sulfur cluster biogenesis (40,42,62), and dyclo-
nine treatment induced iron–sulfur cluster enzyme activity in
animal and cell models (Fig. 5A–C). We also examined several
neurobehavioral parameters in multiple FA mouse models,
including open field activity, grip strength, treadscan and
motor coordination on the level beam task. The most sensitive
behavioral test was time to cross a level beam. Cerebellar
defects in FA patients lead to motor coordination difficulties,
and the level beam test mimics the walking score in the FARS
ataxia score (47). We observed a significant improvement in
this parameter after 4 weeks of oral dyclonine dosing.
Since dyclonine is FDA-approved as an oral rinse, its prescrip-
tion and dispensing was allowed in an IRB-approved trial. Ten
patients were recruited, but 2 did not complete the treatment
and stopped 2–3 days into the study, likely because of the taste
or mouth numbing that persisted for up to 1 h after each dosing.
Of the remaining patients, 6 of the 8 showed an increase in FXN
after 1 week. Additionally, both healthy volunteers responded to
dyclonine with an increase in FXN (Table 2). The correlations
with neurological scores are highly significant, and suggest
that dyclonine produces a greater induction in patients with
more severe FXN deficiency (Fig. 6).
FXN deficiency causes oxidative stress and subsequent cell
death in dorsal root ganglia and cardiac tissue (3). Oxidative
stress is suspected to be important in multiple neurodegenerative
diseases (63–65). Here, we describe a well-known anesthetic
drug dyclonine that protects FA patient cells from diamide-
induced oxidative stress, increases FXN and rescues primary
biochemical end points of the disease in cell and animal models,
and appears to do so involving the Nrf2/ARE pathway. Limita-
tions of this work include translation of beneficial effects seen
in mice to humans, as well as the hope that FXN engagement
after topical exposure with a rinse solution of dyclonine will
model results after a systemic dosing regimen in FA patients.
Although there are a number of questions that need to be addres-
sed for these findings to be clinically applied to patients, includ-
ing a better understanding of pharmacokinetics, optimal dosing
formulation for oral bioavailability and cardiovascular toxicol-
ogy, dyclonine represents a potential novel treatment strategy
for the disease.
MATERIALS ANDMETHODS
Cell lines
Human control and FA patient fibroblasts and lymphoblasts were
obtained from Coriell Institute for Medical Research repository.
Patient lymphoblast cell lines used: GM16214, GM04079,
GM16205, GM16243, GM15850, GM16220 and GM16197.
Patient fibroblast lines used: 1133, 1134.
Diamide screening assay
Patient fibroblasts were grown in MEM media (Life Technolo-
gies Corp.) supplemented with 15% fetal bovine serum in t225
tissue culture flasks and kept below 70% confluency. Cells were
trypsinized and density determined using a Vi-Cell counter
(Beckman Coulter Corp). Five thousand fibroblast cells were
then aliquoted into 96-well poly-D-lysine-coated black/clear
culture plates (Becton Dickinson Corp.) in growth media
without antibiotics in a volume of 180 ml. Cells were allowed
to adhere for 3–4 h at 378C. Drugs (10 mM stock in dimethyl
sulfoxide, DMSO) were dispensed into assay plate wells after
an intermediate dilution in PBS, giving a final DMSO concentra-
tion of 0.1% using an electronic multichannel pipetter (BioHit,
Sartorius Corp.). Pharmakon drug library consisted of 1600
compounds (Microsource Discovery Systems, Inc.) in 96 well
plates at stock concentration of 10 mM in DMSO. Test com-
pounds were all be tested at 10 mM final assay concentration in
primary screen. Eight wells each of 300 mM dithiothreitol
(Sigma-Aldrich Corp.) or 0.1% DMSO were used as positive
or negative controls, respectively. Cells were then incubated at
378C with 5% CO2 overnight. After 24 h, diamide (Sigma-
Aldrich Corp.) was added to all wells at a final concentration
of 125 mM from a 100 mM stock solution prepared in DMSO
and allowed to incubate at 378C with 5% CO2 overnight
(14–18 h). Plates were then washed with PBS, supplemented
with 1 mM Calcein-AM (Molecular Probes, Invitrogen Corp.)
and incubated at room temperature for 45 min. Cells were
again washed with PBS to remove residual dye, and read on
BMG PolarStar Optima with 485 excitation and 520 emission
wavelengths (BMG LabTech).
Western blot analysis
Cells were lysed using lysis buffer (Promega Corp.) supplemen-
ted with a complete protease inhibitor cocktail (Roche Applied
Science) and phenylmethylsulfonyl fluoride (Sigma-Aldrich
Corp.). Tissues were further homogenized using 0.5 mm glass
beads in a Bullet Blender high-throughput homogenizer (Next
Advance, Inc.). After pelleting cellular debris by spinning at
16 000 rpm at 48C for 15 min, protein was quantified by Brad-
ford assay (66). For western blotting, 40–50 mg protein was
added per lane of 4–12% Bis-Tris gels (Invitrogen Corp.).
Primary antibodies were diluted in Odyssey blocking buffer
(LI-COR Biosciences). Antibodies used included: anti-FXN
(provided by Franco Taroni M.D., Istituto Besta), anti-HO1 (#
sc-10789, Santa Cruz Biotechnology, Inc.), anti-NQO1
(#3187, Cell Signaling Technologies), anti-Gpx4 (#ab125066,
AbCam), anti-nrf2 (sc-25820, Santa Cruz) and anti-actin
(#A2668, Sigma). Direct conjugated secondary antibodies (anti-
rabbit IRdye800Cw and anti-mouse IRdye680 from LI-COR)
were used to detect and quantify the signal of primary antibodies
and imaged using a LI-COR Odyssey.
Bioinformatics and phylogenetic analysis of FXN locus
A position weight matrix was used to identify ARE sequences in
FXN based on previously described functional ARE sequences
(28). A pre-filter was used with the consensus sequence of
nnnnnnTGACnnnGCnnnnnn to identify potential ARE sites.
The position weight matrix was used to calculate the score for
each of the pre-filtered hits. Phylogenetic footprinting was
then done using Clustalw2, and a multiple alignment was
done between the great apes (Homo sapiens, Pan troglodytes,
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Figure 5. Dyclonine recovers downstream effects of FXN deficiency in vitro and in vivo. (A) Dyclonine increases aconitase activity in FA patient lymphoblast cell
lines. FA lymphoblasts (GM16205, GM16197 and GM16243) were treated with 10 mM dyclonine or vehicle control (0.1% DMSO). Cell pellets were collected after
48 h, and aconitase activity was measured in lysates over 90 min to ensure linear range was captured. A healthy volunteer lymphoblast cell line was used as a control.
The plotted data represent the mean rate change in fluorescence (dF/dt) from 25 to 30 min. Error bars represent SEM. ∗P, 0.05, t-test. (n ¼ 3). (B) Dyclonine
increases aconitase activity in FA mouse model cerebellum in vivo. FA-YG8 transgenic mice [hFXN+/2 with FXN (GAA)190 expansion; mFxn
2/2] were treated
with 5 mg/kg dyclonine for 1 week p.o. Aconitase activity was measured in cerebellar lysates over 90 min to ensure linear range was captured. Positive controls
were vehicle-treated FA-YG8 transgenic mice [hFXN+/+ with FXN (GAA)190 expansion; mFxn
2/2]. The plotted data represent the mean rate change in fluorescence
(dF/dt) from 15 to 20 min.Error bars represent SEM. ∗P , 0.05, t-test (n ¼ 4 mice per group,11–12 months ofage). (C) Dyclonine increases succinatedehydrogenase
activity in FA mouse model liver in vivo. FA-PandKIKO mice [mFxn+/2with FXN (GAA)230 expansion; mFxn
2/2] were treated with 25 mg/kg dyclonine for 1 week
p.o.Succinate dehydrogenase activity was measured in liver lysates over 90 min. Positive controls were vehicle-treated WT C57/Bl6 mice. The plotted data represent
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Gorilla and Pongo abeli) in the region upstream of the FXN
gene (29).
Chromatin immunoprecipitation
Patient lymphoblasts were seeded at 0.5 × 106/ml in tissue
culture flasks, and incubated with 0.1% DMSO, 5 mM dyclonine
or 5 mM dimethyl-fumarate. About 10 × 106 cells were used
for each condition. After 24 h, cells were treated with 18.5% par-
aformaldehyde to crosslink proteins to DNA. ChIP was per-
formed using an EZ-Chip kit (EMD Millipore). After shearing
by sonication, each cell lysate was split and incubated with
either Anti-Nrf2 (#H-300) or anti-mouse IgG negative control
(Santa Cruz Biotechnology, Inc.) and protein-G-conjugated
agarose beads to immunoprecipitate cross-linked protein/DNA.
Crosslinks were reversed by incubating at 658C overnight, and
DNA was purified with provided spin columns and buffers.
DNA concentration was determined using a Nanodrop 2000c
(Thermo Scientific Corp.), and then analyzed by quantitative
real-time PCR.
Quantitative real-time PCR
Quantitative PCR was performed using the Superscript III One
Step kit (Invitrogen Corp) in a Roche Lightcycler 480 (Roche
Diagnostics). Standard curves were generated for each primer
set, and samples fitted to the linear portion of the curve. Addition-
ally,PCRproductswere runonDNAgels toverifysingle products.
Primer sequences used were described previously and were as
follows: FXNFWD 5′- ATCTTCTCCATCCAGTGGACCT-3′
and FXNREV 5′- GCTGGGCATCAAGCATCTTTT-3′; ARE
16223FWD 5′- CCTGCCGTACTCAGTCCTTC-3′ and ARE
16223REV 5′- CCACTCGGCTGTACTGTCTG-3′; NQO1FWD
5′-CCCTTTTAGCCTTGGCACGAAA-3′ and NQO1REV
5′- TGCACCCAGGGAAGTGTGTTGTAT-3′; HO1FWD 5′
CCCTGCTGAGTAATCCTTTCCCGA-3′ and HO1REV
5′- ATGTCCCGACTCCAGACTCCA-3′ (67).
ARE reporter assay
HeLa cells were treated with Cignal Lenti Reporter ARE-
luciferase lentiviral reagent (SABiosciences, Cat # CLS-
2020L) and underwent selection with 1 mg/ml of puromycin to
generate stable cell line. Hela-ARE stable cells were washed
with PBS and 1× EDTA, and plated in phenol-free DMEM
media supplemented with 10% FBS in white wall/bottom
96-well plates in 90 ml. Plates were incubated at 378C for 2 h
to allow cells to adhere. Drugs or vehicle were added to all
wells (10 ml/well). Cell plates were incubated at 378C for 24 h.
About 75 ml/well of cell lysis/luciferase Bright-Glo reagent
(Promega) were then added to all wells. Wells were mixed
with a biohit electronic pipettor (100 ml 2×). After 5 min with-
out shaking, luminescence was read on BMG Polarstar.
Aconitase assay
Aconitase activity was measured in patient lymphoblast and
mouse model cerebellar lysate using the Aconitase Assay Kit
(Cayman chemicals, Cat # 700600) and performed according
to the manufacturer’s instructions.
Succinate dehydrogenase assay
Succinate dehydrogenase activity was measured (67) in mouse
model liver lysate using the Complex II Enzyme Activity Micro-
plate Assay Kit (Abcam, Cat # ab109908) and performed accord-
ing to the manufacturer’s instructions.
Histone methyltransferase assay
G9 methyltransferase activity was measured in healthy lympho-
blast nuclear extracts (Epiquik Nuclear Extraction Kit, Epigen-
tek, Cat # OP-0002) and using the EpiQuik H3K9 Histone
Methyltransferase Activity/Inhibition Assay Kit (Epigentek,
Cat # P-3003) and performed according to the manufacturer’s
instructions.
Animal procedures and behavioral assessments
All animal procedures wereapprovedby the Institutional Animal
Care and Use Committee at the University of California, Davis
Table 2. Buccal FXN expression in FA patients after treatment with a 1% dyclo-
nine oral rinse
Patient GAA1 GAA2 Fold induction P-value
FRDA4522 600 500 0.4+0.1 0.01
FRDA0055 1178 826 4.8+1.9 0.01
FRDA0171 600 600 3.6+1.7 0.02
FRDA0157 850 850 2.6+1.4 0.01
FRDA0235 1122 230 0.6+0.3 0.02
FRDA4539 1045 670 1.6+0.5 0.07
FRDA4579 1133 71 1.3+0.6 0.31
FRDA4576 800 800 1.8+0.6 0.04
HV0001 ND ND 5.2+1.9 0.02
HV0002 ND ND 1.7+0.3 0.01
Patients and controls were dosed for 1 week with a 1% dyclonine oral rinse, twice
daily for 30 s. Buccal cell samples were taken by clinician use swabs and blinded
prior to analysis. GAA1 and GAA2 refer to the number of GAA repeats in both
alleles of the patient’s FXN gene (ND, not determined). FXN was measured in
blinded samples using dipstick immunoassay normalized to complex IV
expression. Fold induction is a value post-treatment divided by pre-treatment
FXN/CIV+SD (n ¼ 4 measurements per patient).
P-value determined by the t-test.
the mean rate change in fluorescence (dF/dt) from 25 to 30 min. Error bars represent SEM. ∗P , 0.05, t-test (n ¼ 4 mice per group, 8–9 months of age). (D) Dyclonine
improves progressive behavioral defect of FA mice. FA-PandKIKO mice [mFxn+/2 with FXN (GAA)230 expansion; mFxn
2/2] showed a pronounced increase in
beam crossing time compared with WT controls at 13 months of age. FA-PandKIKO mice were treated with 25 mg/kg dyclonine or vehicle for 4 weeks p.o.
Latency to cross a 16 mm beam was the recorded time from start to finish of the beam, with the experimenter blinded to treatment groups. The plotted data represent
the mean latency to cross a beam post-dosing minus the time to cross pre-dosing for each individual mouse and serve as a change from baseline measurement. As a
change from baseline, a negative number means that the animal was faster after dosing than it was before dosing. Positive controls were vehicle-treated WT C57/Bl6
mice. ∗P, 0.05, t-test (n ¼ 7–9 mice per group, 12–14 months of age).
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with adherence to the NIH Guide for the Care and Use of Labora-
tory Animals. The age of mice used for all studies was between 6
and 14 months and was age-matched within experiments. Drug
dosing was done i.p. formulated in a DMSO and PBS mixture,
and p.o. formulated in a DMSO, water and peanut butter mixture.
Behavior testing was performed at the University of California,
Davis Mouse Behavioral Analysis Laboratory. A colony of
YG8R B6.Cg-Fxntm1Mkn Tg(FXN)YG8Pook/J mice was estab-
lished at UC Davis (Jackson Labs, # 012253) (68). For our
testing, we used both hemizygous mice [FA-YG8 (hFXN+/2
with FXN (GAA)190 expansion; mFxn
2/2)] containing one
allele of the mutant FXN transgene and one KO (and thus the
least amount of FXN) and homozygous mice [FA-YG8
(hFXN+/+ with FXN (GAA)190 expansion; mFxn
2/2], contain-
ing two alleles of the transgene (and thus higher levels of FXN),
and wild-type (WT) mice. In addition, the B6.Cg-Fxntm1Mkn
Fxntm1Pand/J strain was also established and used (Jackson
Labs, # 014162), and is referred to as FA-PandKIKO mice
[mFxn+/2 with FXN (GAA)230 expansion; mFxn
2/2] (69,70).
Both of these mice are bred on a C57BL/6J background.
Level beam performance was measured by placing mice on a
100 cm long level beam with a line marked 10 cm from each end
as the start and end lines. A 60 W desk lamp was used as an aver-
sive stimulus at the starting end of the beam, and an enclosed
Figure6.Dyclonine inductionof FXN in buccal cells of FA patients correlateswith disease severity. FA patients were dosed with a 1% dyclonine oral rinse, twice daily
for 30 s. Buccal cells were collected by cheek swabbing before and after 1 week of dosing. Cell lysates were probed by dipstick immunoassay for analysis of FXN
expression and normalized to mitochondrial complex IV (n ¼ 4 replicate experiments of FXN analysis per patient, summarized in Table 1). The plotted data represent
the mean fold change in FXN protein in dyclonine-treated FA patient buccal cells normalized to expression for each individual patient before drug dosing (healthy
volunteers not shown). This fold FXN induction is plotted against (A) FARS score, (B) FDS, (C) Z2 ataxia functional composite score and (D) FXN gene GAA-repeat
length for each FA patient who participated in this clinical study (obtained through a natural history database). For A and B, a higher score indicates greater disease
severity. For C, a lower score indicates greater disease severity. A P-value of ,0.05 is considered significant, Pearson’s correlation coefficient.
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shelter remained at the end of the beam. A training beam of
21 mm diameter was used for three training trials, with at least
10 min of rest allowed for each animal between beam crosses.
Subsequently, three trials were conducted for 21, 16 and 9 mm
wide beams. Time was recorded for each animal to cross from
start to finish. Additionally, a video camera recorded every
trial and was later processed for quantification of foot slips as
errors. Experimenter who recorded times and errors was
blinded to treatment groups.
Clinical human buccal cell collection
Eight FA patients and two healthy volunteers were dosed with a
1% dyclonine oral rinse 2× daily for 30 s for 7 days. Samples
were collected prior to and at the end of 1 week dosing. Buccal
cells were collected from patients and healthy controls using
MasterAmp Buccal Swab brushes (Epicentre, Illumina Corp.).
Swabs were gently twirled against the inside of the right cheek
for 30 s. The swab was then removed from the mouth and
dipped into a tube containing 500 ml of ice cold extraction
buffer (AbCam, #ab109877). The swab brush was placed
gently in the tube of buffer for 10 s to dislodge the cells.
Tubes were frozen at 2208C until all samples received so
FXN measurement could be performed at one time.
FXN immunoassay protocol
FXN expression in buccal cells was measured using a commer-
cially dipstick immunoassay for FXN (AbCam, #ab109877) and
mitochondrial complex IV (AbCam, #ab109881) expression
according to the manufacturer’s instructions. Buccal cells were
lysed using extraction buffer supplied with the assay kit and cel-
lular debris pelleted. Protein concentration was measured by
Bradford assay. About 10 mg of peripheral blood mononu-
cleated cell protein in 25 ml of extraction buffer was mixed
with 25 ml of blocking buffer and added to individual wells on
a 96-well plate with gold-conjugated mAb at the bottom of
each well. Samples were measured as duplicates. After 5 min in-
cubation at room temperature, dipsticks were added into the
well and allowed transfer onto the membrane, where FXN or
complex IV was immunocaptured. This capture was quantified
on dried dipsticks using a Hamamatsu dipstick reader
(AbCam, #MS1000), and raw mABS (milli-Absorbance)
values for FXN were normalized to complex IV raw values.
Statistical analysis
Data are presented as mean+SD or SEM, and the significance
of the difference between groups was evaluated with the Stu-
dent’s t-test (two-tailed) or Pearson’s correlation coefficient. A
P-value of ,0.05 was considered significant. Curve fits were
done using GraphPad prism nonlinear regression analysis with
a variable slope. Additionally, a 95% confidence interval was
used in bioinformatics analysis of ARE sites in FXN gene.
Study approval
The human clinical study was reviewed and approved by the
Investigational Review Board of the University of California,
Los Angeles (proof of concept of dyclonine in buccal cells of
FA patients, UCLA IRB#13-000478). All patients were pro-
vided written informed consent prior to initiation of the study.
All animal studies and procedures were approved by the
Institutional Animal Care and Use Committee at the University
of California, Davis.
SUPPLEMENTARYMATERIAL
Supplementary Material is available at HMG online.
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